MorphoSys AG (MPSYF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MorphoSys AG (MPSYF) trades at $73.27 with AI Score 53/100 (Grade B). MorphoSys AG is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies for cancer and autoimmune diseases. Market cap: $2.76B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for MPSYF: MPSYF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MPSYF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
MPSYF: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
MorphoSys AG (MPSYF) Healthcare & Pipeline Overview
MorphoSys AG is a German biopharmaceutical company specializing in therapeutic antibody development for cancer and autoimmune diseases, with Tafasitamab as its key commercial product and a pipeline of clinical-stage assets, positioning it within the competitive biotechnology landscape focused on innovative therapies.
What Is the Investment Thesis for MPSYF?
MorphoSys AG presents a compelling investment case based on its commercial-stage status with Tafasitamab, generating revenue in the B-cell malignancy market. The company's pipeline, including Pelabresib and Felzartamab, offers potential upside through successful clinical trials and subsequent commercialization. Key value drivers include the expansion of Tafasitamab's market share and label, positive clinical data from ongoing trials, and strategic partnerships. The company's gross margin of 75.5% indicates strong pricing power. However, investors should be aware of the negative profit margin of -79.6%, indicating high operating expenses. Upcoming clinical trial results for Pelabresib in myelofibrosis and Felzartamab in membranous nephropathy represent key catalysts. Potential risks include clinical trial failures, regulatory hurdles, and competition from established players.
Based on FMP financials and quantitative analysis
MPSYF Key Highlights
Market capitalization of $2.76B reflects investor valuation of MorphoSys's commercial product and pipeline.
- Gross margin of 75.5% indicates strong pricing power and efficient cost management in antibody production.
- Negative P/E ratio of -11.89 due to current losses, reflecting investment in R&D and commercialization efforts.
- Beta of 0.66 suggests lower volatility compared to the overall market, potentially appealing to risk-averse investors.
- Tafasitamab is approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide, addressing a significant unmet need.
Who Are MPSYF's Competitors?
MPSYF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ASPHF Ascentage Pharma Group International | $4.53 | +0.00% | $1.69B | 51 |
| BIESF Biotest AG | $32.00 | +0.00% | $1.60B | 48 |
| INVVY Indivior PLC | $21.85 | +0.00% | $3.01B | 47 |
| IZQVF Indivior PLC | $20.97 | +0.00% | $2.89B | — |
| MYOV Myovant Sciences Ltd. | $26.98 | -0.04% | $2.62B | 71 |
| ARQT Arcutis Biotherapeutics, Inc. | $25.35 | -4.20% | $3.17B | 89 |
| MBX MBX Biosciences | $68.40 | +2.83% | $3.26B | 74 |
| VCYT Veracyte, Inc. | $41.79 | -0.95% | $3.33B | 96 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MPSYF's Key Strengths?
Commercial-stage company with Tafasitamab generating revenue.
- Strong pipeline of clinical-stage drug candidates.
- Proprietary antibody discovery and development technologies.
- Established partnerships with leading pharmaceutical companies.
What Are MPSYF's Weaknesses?
Negative profit margin due to high R&D and commercialization expenses.
- Reliance on Tafasitamab for revenue generation.
- Competition from established players in the biotechnology industry.
- Risk of clinical trial failures.
What Could Drive MPSYF Stock Higher?
Phase II clinical trial results for Pelabresib in myelofibrosis expected in late 2026.
- Phase II data for Felzartamab in anti-PLA2R-positive membranous nephropathy expected in late 2026.
- Expansion of Tafasitamab's label to other B-cell malignancies.
- Advancement of CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2.
- Strategic partnerships and licensing agreements to expand pipeline and market reach.
What Are the Key Risks for MPSYF?
Financial-distress signal — its Altman Z-Score of -1.11 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Pelabresib, Felzartamab, or other pipeline candidates.
- Regulatory hurdles and delays in obtaining approvals for new drugs.
- Competition from established players in the biotechnology industry.
- Pricing pressures and reimbursement challenges for Tafasitamab and other therapies.
- Dependence on key partnerships, such as with Incyte Corporation.
What Are the Growth Opportunities for MPSYF?
- Expansion of Tafasitamab's Label and Market Share: Tafasitamab, currently approved for relapsed or refractory DLBCL, has the potential for label expansion to other B-cell malignancies, such as follicular lymphoma and marginal zone lymphoma. This expansion could significantly increase its market share, addressing a broader patient population. The market for B-cell lymphoma therapies is estimated to reach $15 billion by 2028, providing a substantial opportunity for MorphoSys. Timeline: Ongoing clinical trials and regulatory submissions.
- Development and Commercialization of Pelabresib: Pelabresib, a small molecule in Phase II clinical trials for myelofibrosis, represents a significant growth opportunity. Myelofibrosis is a rare bone marrow cancer with limited treatment options, creating a high unmet need. Positive clinical trial results and subsequent regulatory approval could lead to substantial revenue generation. The myelofibrosis market is projected to reach $2.5 billion by 2027. Timeline: Phase III trials expected to commence in 2026, potential commercialization by 2028.
- Advancement of Felzartamab for Autoimmune Diseases: Felzartamab, an anti-CD38 antibody, is being developed for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. Success in clinical trials could position Felzartamab as a novel therapy in this underserved market. The market for membranous nephropathy treatments is estimated at $500 million, with potential for growth. Timeline: Phase II data expected in late 2026, potential commercialization by 2029.
- Strategic Partnerships and Licensing Agreements: MorphoSys has a history of successful partnerships, such as its collaboration with Incyte Corporation for Tafasitamab. Pursuing additional strategic alliances and licensing agreements can provide access to new technologies, expand its pipeline, and accelerate commercialization efforts. These partnerships can also provide non-dilutive funding for research and development. Timeline: Ongoing, with potential for new agreements in the next 1-3 years.
- Expansion into New Therapeutic Areas: While MorphoSys primarily focuses on cancer and autoimmune diseases, exploring opportunities in other therapeutic areas, such as neurodegenerative diseases or infectious diseases, could diversify its pipeline and reduce its reliance on a limited number of indications. This diversification could mitigate risks associated with clinical trial failures in its core areas. Timeline: Long-term, with potential for new programs to emerge in the next 3-5 years.
What Are MPSYF's Competitive Advantages?
- Proprietary antibody discovery and development technologies.
- Strong intellectual property portfolio protecting its drug candidates.
- Established partnerships with leading pharmaceutical companies.
- Commercial infrastructure for Tafasitamab sales and marketing.
- Clinical expertise in oncology and immunology.
What Does MPSYF Do?
MorphoSys AG, founded in 1992 and headquartered in Planegg, Germany, is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutic antibodies. The company focuses on addressing unmet medical needs in cancer and autoimmune diseases. Its lead commercial product is Tafasitamab (marketed as Monjuvi in the US and Minjuvi in Europe), an antibody used in the treatment of B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and marginal zone lymphoma. Tafasitamab was developed in collaboration with Incyte Corporation. MorphoSys also has a pipeline of other therapeutic candidates in various stages of clinical development. These include Pelabresib, a small molecule in Phase II clinical trials for myelofibrosis; Felzartamab, an anti-CD38 antibody in Phase I/II trials for anti-PLA2R-positive membranous nephropathy; and CPI-0209, a small molecule EZH2 inhibitor in Phase I/II trials. Additionally, MorphoSys partners with other pharmaceutical companies to develop and commercialize other antibodies, such as Gantenerumab for Alzheimer's disease (through pharmaceutical partners), Otilimab for rheumatoid arthritis, and Tremfya for psoriasis and psoriatic arthritis. MorphoSys operates primarily in the United States and Europe, with strategic collaborations extending its reach into other global markets.
What Products and Services Does MPSYF Offer?
- Discovers and develops therapeutic antibodies for cancer and autoimmune diseases.
- Commercializes Tafasitamab for the treatment of B-cell malignancies.
- Conducts clinical trials for its pipeline of drug candidates.
- Partners with other pharmaceutical companies to develop and commercialize antibodies.
- Focuses on addressing unmet medical needs in oncology and immunology.
- Utilizes proprietary technologies for antibody discovery and development.
- Engages in research and development to identify new therapeutic targets.
How Does MPSYF Make Money?
- Develops and commercializes its own proprietary therapeutic antibodies.
- Generates revenue through sales of Tafasitamab.
- Out-licenses its antibody technologies and drug candidates to other pharmaceutical companies.
- Receives milestone payments and royalties from its partnerships.
What Industry Does MPSYF Operate In?
MorphoSys AG operates in the highly competitive biotechnology industry, characterized by intense research and development, lengthy clinical trial processes, and stringent regulatory requirements. The market for therapeutic antibodies is experiencing significant growth, driven by advancements in immunotherapy and targeted therapies. Key competitors include companies like ARHCF, ASPHF, BIESF, INVVY, and IZQVF, which are also developing novel therapies for cancer and autoimmune diseases. The industry is subject to evolving regulatory landscapes and pricing pressures, impacting profitability and market access. MorphoSys's success depends on its ability to innovate, secure regulatory approvals, and effectively commercialize its products.
Who Are MPSYF's Key Customers?
- Patients suffering from cancer and autoimmune diseases.
- Hospitals and oncology clinics.
- Specialty pharmacies.
- Pharmaceutical companies through licensing agreements.
MorphoSys AG Financial Trajectory
MorphoSys AG (MPSYF) reported $34.6M in revenue for Q2 2024, reflecting 25.8% growth compared to the prior quarter. The company recorded a net loss of $79.2M, with diluted EPS of $-2.14.
Company Profile
MorphoSys AG operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Planegg, DE. The company is led by CEO Arkadius Pichota. MPSYF has traded publicly since 2010.
How MorphoSys AG Is Valued
MorphoSys AG carries a market capitalization of $2.76B, placing it in the mid-cap category. Relative to its peer group, MPSYF's quantitative score of 53/100 is roughly in line with the peer average of 54/100.
Key Financial Metrics
Return on assets is -9.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -11.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.08 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
MorphoSys AG's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.11 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
MorphoSys AG has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 15.7% above estimates on average.
Forward Outlook
Wall Street analysts project MorphoSys AG revenue of about $461.8M for fiscal 2026, with EPS near $-2.21.
MPSYF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Commercial-stage company with Tafasitamab generating revenue.
- Strong pipeline of clinical-stage drug candidates.
- Proprietary antibody discovery and development technologies.
- Established partnerships with leading pharmaceutical companies.
Bear Case
- Negative profit margin due to high R&D and commercialization expenses.
- Reliance on Tafasitamab for revenue generation.
- Competition from established players in the biotechnology industry.
- Risk of clinical trial failures.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2024 | $35M | -$79M | -$2.14 |
| Q1 2024 | $28M | -$315M | -$8.37 |
Based on FMP financials and quantitative analysis
MPSYF Latest News
No recent news available for MPSYF.
MPSYF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MPSYF.
Price Targets
Wall Street price target analysis for MPSYF.
MPSYF MoonshotScore
What does this score mean?
The MoonshotScore rates MPSYF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Arkadius Pichota
Unknown
Information on Arkadius Pichota's background is not available in the provided data. Without additional context, it's impossible to accurately describe his career history, education, or previous roles.
Track Record: Information on Arkadius Pichota's track record is not available in the provided data. Without additional context, it's impossible to accurately describe his key achievements, strategic decisions, or company milestones under his leadership.
MPSYF OTC Market Information
The OTC Other tier, also known as the Pink Market, represents the lowest tier of the over-the-counter (OTC) market. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier often have limited or no reporting requirements. This tier is generally reserved for companies that do not meet the minimum financial standards or choose not to comply with the listing requirements of higher-tier OTC markets or national exchanges. Investing in companies on the OTC Other tier carries significantly higher risks due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in MPSYF.
- Lower liquidity can lead to price volatility and difficulty in trading shares.
- OTC Other companies may be subject to less regulatory oversight, increasing the risk of fraud or mismanagement.
- The lack of minimum listing standards can indicate financial instability or operational challenges.
- Information asymmetry can make it difficult to assess the true value of the company.
- Verify the company's registration and legal standing.
- Review any available financial statements, even if limited.
- Assess the company's business model and competitive landscape.
- Research the background and experience of the company's management team.
- Evaluate the company's capital structure and potential dilution risks.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor before investing.
- The company has been in operation since 1992, suggesting some level of stability.
- MorphoSys has partnerships with established pharmaceutical companies, indicating some level of credibility.
- The company has a commercial product (Tafasitamab) generating revenue.
- MorphoSys has a pipeline of drug candidates in clinical development, suggesting ongoing research and innovation.
What Investors Ask About MorphoSys AG (MPSYF) — Healthcare
What does the AI Score mean for MPSYF?
MPSYF holds an AI Score of 53/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. MorphoSys AG is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies for cancer and autoimmune diseases. Their lead product …
What does MorphoSys AG do?
MorphoSys AG is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic antibodies for the treatment of cancer and autoimmune diseases. Its primary product is Tafasitamab, an antibody approved for certain B-cell malignancies. The company also has a pipeline of drug candidates in various stages of clinical development, targeting conditions like myelofibrosis and membranous nephropathy.
What are the main risks for MPSYF?
The main risks for MorphoSys AG include the potential for clinical trial failures, which could significantly impact the value of its pipeline. Regulatory hurdles and delays in obtaining approvals for new drugs also pose a risk. Competition from established players in the biotechnology industry, as well as pricing pressures and reimbursement challenges, could affect the commercial success of its products.
What are the key factors to evaluate for MPSYF?
MorphoSys AG (MPSYF) holds an AI score of 53/100 (moderate). MorphoSys AG presents a compelling investment case based on its commercial-stage status with Tafasitamab, generating revenue in the B-cell malignancy market. Not financial advice.
How frequently does MPSYF data refresh on this page?
MPSYF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MPSYF's recent stock price performance?
MorphoSys AG (MPSYF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Commercial-stage company with Tafasitamab generating revenue. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MPSYF overvalued or undervalued right now?
MorphoSys AG (MPSYF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MPSYF before investing?
Before investing in MorphoSys AG (MPSYF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding MPSYF to a portfolio?
Key strength of MorphoSys AG (MPSYF): Commercial-stage company with Tafasitamab generating revenue. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on provided source data as of 2026-03-17.
- OTC market data may be limited or delayed.
- AI analysis is pending and may provide further insights.